Compare · CRMD vs NEXT
CRMD vs NEXT
Side-by-side comparison of CorMedix Inc. (CRMD) and NextDecade Corporation (NEXT): market cap, price performance, sector, and recent activity on the wire.
Summary
- CRMD operates in Health Care, while NEXT operates in Utilities - the two are in different parts of the market.
- NEXT is the larger of the two at $1.60B, about 10.3x CRMD ($155.0M).
- Over the past year, CRMD is down 28.5% and NEXT is up 3.0% - NEXT leads by 31.4 points.
- NEXT has been more active in the news (3 items in the past 4 weeks vs 2 for CRMD).
- NEXT has more recent analyst coverage (16 ratings vs 8 for CRMD).
- Company
- CorMedix Inc.
- NextDecade Corporation
- Price
- $7.28-2.48%
- $6.27+4.33%
- Market cap
- $155.0M
- $1.60B
- 1M return
- -6.31%
- -10.36%
- 1Y return
- -28.49%
- +2.96%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Oil & Gas Production
- Exchange
- AMEX
- NASDAQ
- IPO
- 2015
- News (4w)
- 2
- 3
- Recent ratings
- 8
- 16
CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
NextDecade Corporation
NextDecade Corporation, a liquefied natural gas (LNG) development company, engages in the development activities related to the liquefaction and sale of LNG. It focusses on the development activities of Rio Grande LNG terminal facility located in the Port of Brownsville, southern Texas. The company is headquartered in Houston, Texas.
Latest CRMD
- Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
- Oppenheimer initiated coverage on Cormedix with a new price target
- Director Dillione Janet converted options into 48,909 shares, increasing direct ownership by 71% to 117,835 units (SEC Form 4)
- Chief Financial Officer Blum Susan covered exercise/tax liability with 8,424 shares, decreasing direct ownership by 6% to 124,315 units (SEC Form 4)
- Chief Operating Officer Hurlburt Elizabeth covered exercise/tax liability with 8,076 shares, decreasing direct ownership by 3% to 270,463 units (SEC Form 4)
- Chief Legal Officer Zelnick Kaufman Beth covered exercise/tax liability with 8,424 shares, decreasing direct ownership by 3% to 260,684 units (SEC Form 4)
- CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
- Today's Stocks in the News
- SEC Form 10-Q filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NEXT
- SEC Form 4 filed by NextDecade Corporation
- NextDecade Announces Timing of Third Quarter 2026 Investor Call
- SEC Form 8-K filed by NextDecade Corporation
- Chief Operating Officer Skeik Tarik covered exercise/tax liability with 7,732 shares, decreasing direct ownership by 2% to 355,542 units (SEC Form 4) to satisfy withholding obligation
- General Counsel De Gyarfas Vera covered exercise/tax liability with 15,463 shares, decreasing direct ownership by 2% to 955,103 units (SEC Form 4) (tax liability)
- Chief Executive Officer Schatzman Matthew K covered exercise/tax liability with 69,583 shares, decreasing direct ownership by 1% to 5,319,526 units (SEC Form 4) to satisfy tax liability
- Chief Operating Officer Skeik Tarik was granted 99,469 shares and covered exercise/tax liability with 18,043 shares, increasing direct ownership by 29% to 363,274 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Schatzman Matthew K was granted 464,190 shares and covered exercise/tax liability with 135,928 shares, increasing direct ownership by 6% to 5,667,115 units (SEC Form 4) to cover taxes
- General Counsel De Gyarfas Vera was granted 132,625 shares and covered exercise/tax liability with 30,378 shares, increasing direct ownership by 11% to 1,032,345 units (SEC Form 4) to cover taxes
- Chief Accounting Officer Boylston Luke was granted 23,872 shares and covered exercise/tax liability with 6,563 shares, increasing direct ownership by 8% to 236,818 units (SEC Form 4) (tax withholding)